About RadioMedix
RadioMedix, Inc. is a clinical stage biotechnology company, based in Houston, Texas, focused on innovative targeted radiopharmaceuticals for diagnosis, monitoring and therapy of cancer. The company is commercializing generator-produced radiopharmaceuticals based on Gallium-68 chemistry for PET imaging and therapeutic (Alpha and Beta-emitter labeled) radiopharmaceuticals for targeted radionuclide therapy in cancer. RadioMedix has also established two service facilities for academic and industrial partners: cGMP manufacturing suite for human clinical trials and probe development and small animal molecular imaging facility for evaluation of agents in animal models. More information at http://www.radiomedix.com
Ad Statistics
Times Displayed: 20910
Times Visited: 407 Stay up to date with the latest training to fix, troubleshoot, and maintain your critical care devices. GE HealthCare offers multiple training formats to empower teams and expand knowledge, saving you time and money
About Excel Diagnostics and Nuclear Oncology Center
Excel Diagnostics & Nuclear Oncology Center is one of the U.S. leading diagnostic imaging and therapeutic facilities located in Houston, Texas. Excel utilizes the latest generation of imaging equipment and offers a full range of imaging modalities. In addition to its comprehensive imaging services, Excel has required infrastructure to perform pioneer investigational clinical trials in the field of diagnostic molecular imaging and targeted radionuclide therapy. More information at http://www.exceldiagnostics.com
About the Ahmanson Translational Imaging Division at UCLA
Ahmanson Translational Imaging Division at the University of California, Los Angeles (UCLA) is specialized on molecular PET imaging, radioligand therapy and new theranostic concepts combining their profound expertise in preclinical imaging, drug development and the clinical translation of innovative diagnostic and therapeutic radionuclides. More information at http://www.pet.ucla.edu/
Back to HCB News
